PMV PHARMACEUTICALS I

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

07 11 2024 08:00:01 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

23 10 2024 08:00:01 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial

08 8 2024 08:00:01 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June

30 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

29 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

09 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

27 3 2024 08:00:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

18 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

29 2 2024 16:01:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

26 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

18 1 2024 16:01:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

05 1 2024 16:01:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

09 11 2023 08:00:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

12 10 2023 12:30:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

11 10 2023 12:00:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

20 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

09 8 2023 08:00:01 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

06 6 2023 16:01:00 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

10 5 2023 08:00:01 提供 Nasdaq GlobeNewswire

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

01 3 2023 08:00:02 提供 Nasdaq GlobeNewswire